COMMUNIQUÉS West-GlobeNewswire

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
20/10/2026
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio REYKJAVIK, Iceland and LONDON, UK (October 20, 2026) - Alvotech (NASDAQ: ALVO [...]
Aqua free élargit sa gamme de produits : le nouveau Baclyser® neo T Max pour une capacité et une efficacité accrues
20/10/2026
Hamburg, Germany, 20 oct. 2026 (GLOBE NEWSWIRE) -- Hambourg, [date] – Avec le nouveau Baclyser® neo T Max , Aqua free présente la toute dernière évolution de sa gamme éprouvée de filtres stériles Baclyser® neo . Ce [...]
Aqua free expands its product portfolio: New Baclyser® neo T Max offers greater capacity and efficiency
20/10/2026
Hamburg, Germany, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Hamburg, 20.10.2026 – Aqua free introduces the new Baclyser® neo T Max , the latest addition to its established Baclyser® neo range of sterile water filters. This [...]
Maxion Therapeutics Appoints Biopharma Leader Mikael Dolsten to Board of Directors
20/10/2026
Former Pfizer Chief Scientific Officer and President of Worldwide Research, Development and Medical brings deep experience translating scientific innovation into life-changing medicines for patients CAMBRIDGE, United [...]
KFSH Brings Cardiac Catheterization Directly to Emergency Department to Accelerate Critical Care
20/10/2026
RIYADH, Saudi Arabia, Oct. 20, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has established a dedicated Cardiac Catheterization Lab within the Emergency Department at its Riyadh [...]
Orikine Presents Preclinical Data Demonstrating Sustained Myeloid Reprogramming and Disease Control with ORK1 in Inflammatory Bowel Disease at UEG Week 2026
20/10/2026
A single dose of ORK1 generated durable disease control in two independent inflammatory bowel disease mouse models ORK1 induced sustained myeloid reprogramming, regulating chronic inflammation This data supports further [...]
Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026
20/10/2026
Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates Allschwil, Switzerland, October 20, [...]
Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million, Expanding its Rare Disease Pipeline and Gaining a European Base
20/10/2026
, Oct. 20, 2026 (GLOBE NEWSWIRE) -- CAMBRIDGE, UK & UTRECHT, THE NETHERLANDS – October 20, 2026 – Ambrose Healthcare, a rare disease specialist, has acquired 100% of the shares of AM-Pharma. Under the terms of the [...]
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
20/10/2026
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS [...]
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
20/10/2026
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS [...]
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
20/10/2026
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory [...]
Leo International Precision Health AG: Mr Leo Wang, Disposal
19/10/2026
Leo International Precision Health AG: Mr Leo Wang, Disposal Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 19. Oct 2026 [...]
XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire
20/10/2026
L’étude sponsorisée par des chercheurs et financée par l’Institut National du Cancer (INCa) atteint le critère de jugement principal d’efficacité préspécifié, avec une survie globale à 12 mois de 61,3 %. L’analyse [...]
KFSH Cuts Emergency Department Boarding Time by 75% Through AI-Enabled Patient Flow System
20/10/2026
RIYADH, Saudi Arabia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced median Emergency Department boarding time at its Riyadh hospital by 75%, from more than 13 [...]
Remote Heart Monitoring at KFSH Reduces Heart Failure Admissions by 46%
20/10/2026
RIYADH, Saudi Arabia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced hospital admissions for decompensated heart failure by 46.4% among patients fitted with an [...]
Marriott Foundation invests $4 million in Children’s National mental healthcare
19/10/2026
The gift from The J. Willard and Alise S. Marriot Foundation increases access to mental healthcare through Children’s National primary care locations and Pediatric Health Network practices, ensuring more families [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of [...]
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
19/10/2026
NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic [...]
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
19/10/2026
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments [...]

Pages